Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVA-SARS-2-S Vaccine and Comirnaty Booster in Healthy Volunteers
NCT04569383Phase 1Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2020
- Primary completion
- Aug 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of MVA-SARS-2-S in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Percentage of Participants Experiencing Solicited Local or Systemic Reactogenicity up to 6 months. Started Oct 2020; status: completed.
02
Drugs
MVA-SARS-2-S
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04569383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569383.